Migraine With Aura clinical trials

Explore recruiting migraine with aura clinical trials.

Recruiting migraine with aura studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Migraine With Aura trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

ASIC Channels and Migraine Disease - Proof-of-Concept Study on the Efficacy of Amiloride in Migraine Aura Prophylaxis

France

Phase II and Phase III (Integrated) EU CTIS Study details

A Study to Compare the Blood Levels of Two Dosage Formulations of the Study Medicine in Healthy Adults

Belgium

Human Pharmacology (Phase I)- Bioequivalence Study EU CTIS Study details

A Phase 3, Multicenter, 12-Week, Double Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Atogepant for the Preventive Treatment of Episodic Migraine in Pediatric Subjects 6 to 17 years of age

Sweden, Hungary, Belgium, Denmark, Italy, France +4 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Randomized, Double-Blind, Placebo-Controlled, Multiple-Attack Study with an Open-Label Extension to Evaluate the Efficacy, Safety, Tolerability, and the Consistency of Effect of Atogepant for the Acute Treatment of Migraine (ECLIPSE)

Spain, Germany, Poland, Czechia, Belgium, Slovakia +4 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 3, Multicenter, Open-Label 156-Week Extension Study To Evaluate The Long-Term Safety And Tolerability Of Oral Atogepant For The Prevention Of Migraine In Participants With Chronic Or Episodic Migraine

Spain, Denmark, Germany, Hungary, France, Netherlands +3 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Multicenter, Open-label, Extension Study to Evaluate the Long-term Safety and Tolerability of Atogepant in Pediatric Subjects 6 to 17 years of age with Migraine

Belgium, Denmark, Italy, Netherlands, Poland, Spain +5 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Migraine With Aura trials by city

Migraine With Aura in Toronto Migraine With Aura in Vancouver Migraine With Aura in Montreal Migraine With Aura in Calgary Migraine With Aura in Edmonton Migraine With Aura in Ottawa Migraine With Aura in Winnipeg Migraine With Aura in Quebec City Migraine With Aura in Hamilton Migraine With Aura in Kitchener Migraine With Aura in London Migraine With Aura in Halifax Migraine With Aura in New York Migraine With Aura in Los Angeles Migraine With Aura in Chicago Migraine With Aura in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease